HHN_179-17

Pilot program to assess the potential role of pharmacogenomics to improve drug safety in patients with advanced cancer.

The purpose of this study is to determine if a drug safety program based on pharmacogenetics (the study of how a person’s genes respond to drugs), can limit the drug interactions and adverse drug reactions.
N/A
All Other|Cancer
Multiple Tumor Types
Michael Demeure, M.D.
  • xSJH Southern California